GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 07 2020
03 07 2020
Historique:
received:
13
01
2020
accepted:
03
06
2020
entrez:
5
7
2020
pubmed:
6
7
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Preclinical models that reliably recapitulate the immunosuppressive properties of human gliomas are essential to assess immune-based therapies. GL261 murine glioma cells are widely used as a syngeneic animal model of glioma, however, it has become common practice to transfect these cells with luciferase for fluorescent tumor tracking. The aim of this study was to compare the survival of mice injected with fluorescent or non-fluorescent GL261 cells and characterize the differences in their tumor microenvironment. Mice were intracranially implanted with GL261, GL261 Red-FLuc or GL261-Luc2 cells at varying doses. Cytokine profiles were evaluated by proteome microarray and Kaplan-Meier survival analysis was used to determine survival differences. Median survival for mice implanted with 5 × 10
Identifiants
pubmed: 32620877
doi: 10.1038/s41598-020-67411-w
pii: 10.1038/s41598-020-67411-w
pmc: PMC7335060
doi:
Substances chimiques
Cytokines
0
Luciferases
EC 1.13.12.-
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
11003Commentaires et corrections
Type : ErratumIn
Références
Drug Discov Today. 2019 May;24(5):1193-1201
pubmed: 30878561
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9
pubmed: 23462419
Sci Rep. 2017 Aug 10;7(1):7715
pubmed: 28798322
Oncologist. 2017 May;22(5):585-591
pubmed: 28438889
J Natl Cancer Inst. 2014 Jun 28;106(8):
pubmed: 24974128
Neuro Oncol. 2015 Nov;17 Suppl 7:vii9-vii14
pubmed: 26516226
J Neurooncol. 2009 May;93(1):107-14
pubmed: 19430886
Oncologist. 2017 Nov;22(11):1392-1399
pubmed: 28835513
Cancer Immunol Res. 2013 Aug;1(2):112-22
pubmed: 24409449
Oncotarget. 2017 May 15;8(37):61072-61082
pubmed: 28977847
J Transl Med. 2014 Apr 29;12:107
pubmed: 24779345
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Biochem Pharmacol. 2017 Apr 15;130:1-9
pubmed: 28017775
Clin Cancer Res. 2017 Jan 1;23(1):124-136
pubmed: 27358487
Neurosurg Clin N Am. 2012 Apr;23(2):307-22, ix
pubmed: 22440874
PLoS One. 2014 Jul 11;9(7):e101764
pubmed: 25013914
Med Sci Monit. 2017 Jul 24;23:3593-3602
pubmed: 28736431
PLoS One. 2014 Nov 04;9(11):e109956
pubmed: 25369133
Oncoimmunology. 2018 May 24;7(8):e1466769
pubmed: 30221069
Science. 1993 Jan 15;259(5093):368-70
pubmed: 7678351
Cancer Immunol Res. 2016 Feb;4(2):124-35
pubmed: 26546453
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Neuro Oncol. 2016 May;18(5):639-48
pubmed: 26658052
PLoS One. 2015 May 01;10(5):e0125565
pubmed: 25933216
Clin Cancer Res. 2008 Aug 15;14(16):5166-72
pubmed: 18698034
J Immunother. 2011 Apr;34(3):264-9
pubmed: 21389872
Cell Cycle. 2004 Feb;3(2):230-4
pubmed: 14712094
Cancers (Basel). 2014 Sep 29;6(4):1953-85
pubmed: 25268164
Clin Dev Immunol. 2013;2013:952469
pubmed: 23710206
Neuro Oncol. 2012 May;14(5):584-95
pubmed: 22406925
Neuro Oncol. 2015 Jul;17(7):978-91
pubmed: 25537019
Cancer Biol Ther. 2007 May;6(5):781-6
pubmed: 17495521
J Neurooncol. 2019 Jun;143(2):241-249
pubmed: 31025274
Cancer Sci. 2006 Jun;97(6):546-53
pubmed: 16734735
Cell Immunol. 1997 Jun 15;178(2):101-7
pubmed: 9225000
J Transl Med. 2014 Dec 03;12:345
pubmed: 25464980